Targeting vulnerabilities in copper metabolism in the development of cancer therapies
针对癌症疗法开发中铜代谢的脆弱性
基本信息
- 批准号:10683333
- 负责人:
- 金额:$ 47.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-03 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:4T1AddressAffinityAnimal ModelArtificial MembranesBindingBinding SitesBiologicalBiological AssayBiological AvailabilityBiological MarkersBreast Cancer CellBreast Cancer ModelBreast Cancer PatientCancer ModelCancer PatientCancer cell lineCell Membrane PermeabilityCeruloplasminChelating AgentsClinicalClinical ResearchClinical TrialsComputer AssistedCopperDetectionDevelopmentDietDisease ProgressionDoseDrug DesignDrug KineticsERBB2 geneEnzymesEvaluationFamilyGoalsGrowthHot SpotIn VitroIntestinesLeadLiver MicrosomesMAP2K1 geneMalignant NeoplasmsMaximum Tolerated DoseMesotheliomaMetabolicMetabolismMetastatic breast cancerMicronutrientsModelingMolecular ConformationMonitorMouse Mammary Tumor VirusMusNeoplasm MetastasisNormal tissue morphologyNutrientOncogenicOralPathway interactionsPatientsPerformancePermeabilityPharmaceutical PreparationsPharmacodynamicsPhasePhosphotransferasesPre-Clinical ModelPredispositionPrimary NeoplasmProcessPropertyProtein-Lysine 6-OxidaseProteinsPublishingRoleSerumStructureStructure-Activity RelationshipTestingTherapeuticTimeTissuesTreatment Efficacyabsorptionanaloganti-cancercancer cellcancer therapycell motilitychelationdesignexperimental studyfunctional grouphigh risk populationhuman modelimprovedinhibitorinnovationlead optimizationlung cancer cellmalignant breast neoplasmmouse modelnanomolarneoplastic cellnovelnovel therapeutic interventionoxidationpreclinical developmentscreeningsmall moleculesmall molecule inhibitortherapeutic targettherapy developmenttriple-negative invasive breast carcinomatumortumor growthvalidation studies
项目摘要
PROJECT SUMMARY
Although there have been important advances in the detection and treatment of cancer, there remains an
urgent need to develop new therapeutic strategies. Copper (Cu) is an essential micronutrient that is required in
higher amounts by cancer cells relative to normal tissues. Several enzymes with key roles in cancer require
Cu for their activity, including lysyl oxidases and several oncogenic kinases (e.g., MEK1; ULK1). In pre-clinical
models of cancer, many studies have shown that tumor growth and metastasis is suppressed by Cu chelators
added to the diet. In clinical trials, Cu depletion via an oral Cu chelator was found to significantly slow disease
progression in patients with mesothelioma, and significantly extend survival in breast cancer patients. While it
is clear that Cu depletion is a promising anticancer strategy, there is a need to develop therapies that
specifically target pathways of Cu delivery to oncogenic enzymes. In the current proposal, we pursue a highly
innovative approach by targeting the Cu transporter, ATP7A.
Our extensive preliminary studies validate ATP7A as a therapeutic target including: 1) Intestine-specific
deletion of murine ATP7A lowers systemic copper status to levels shown to be therapeutic in cancer patients;
2) ATP7A is required to deliver copper to the family of lysyl oxidases, which have well-documented roles in
metastasis; 3) Targeted deletion of ATP7A in breast and lung cancer cell lines reduces primary tumor growth
and metastasis in mice; 4) Elevated ATP7A expression is significantly correlated with lower survival in cancer
patients. Based on these findings, we hypothesize that a small molecule inhibitor of ATP7A will be
therapeutic in cancer. Using computer-aided drug design, we have identified a hit molecule called MKV3 that
binds to ATP7A with nanomolar affinity and inhibits ATP7A activity in cancer cell lines. Mice treated with MKV3
showed reduced activity of the serum Cu biomarker, ceruloplasmin, and reduced tumor growth. In this
proposal, we will conduct structure guided optimization to identify MKV3 analogs with improved potency and
drug like properties (Aim 1); conduct pharmacokinetic studies to identify MKV3 analogs that are suitable for
pharmacodynamic studies (Aim 2); and evaluate the most favorable MKV3 analog in mouse models of breast
cancer (Aim 3).
项目摘要
尽管在癌症的检测和治疗方面已经有了重要的进展,但仍然存在一个问题。
迫切需要开发新的治疗策略。铜(Cu)是一种必需的微量营养素,
相对于正常组织,癌细胞的含量更高。几种在癌症中起关键作用的酶需要
Cu的活性,包括赖氨酰氧化酶和几种致癌激酶(例如,MEK1; ULK1)。在临床前
癌症模型,许多研究表明,肿瘤生长和转移抑制铜螯合剂
添加到饮食中。在临床试验中,通过口服铜螯合剂消耗铜被发现可以显着减缓疾病
在间皮瘤患者中的进展,并显著延长乳腺癌患者的生存期。虽然
显然,铜消耗是一种有前途的抗癌策略,需要开发
特异性地靶向Cu递送至致癌酶的途径。在目前的提案中,我们追求一个高度
通过靶向铜转运蛋白ATP 7A的创新方法。
我们广泛的初步研究验证了ATP 7A作为治疗靶点,包括:1)肠特异性
鼠ATP 7A的缺失将全身铜状态降低至显示在癌症患者中具有治疗性的水平;
2)ATP 7A是将铜传递给赖氨酰氧化酶家族所必需的,赖氨酰氧化酶家族在以下方面具有充分记载的作用:
3)乳腺癌和肺癌细胞系中ATP 7A的靶向缺失减少原发性肿瘤生长
4)ATP 7A表达升高与癌症中较低的存活率显著相关
患者基于这些发现,我们假设ATP 7A的小分子抑制剂将是一种有效的抑制剂。
治疗癌症。使用计算机辅助药物设计,我们已经确定了一种名为MKV 3的命中分子,
以纳摩尔亲和力结合ATP 7A并抑制癌细胞系中的ATP 7A活性。用MKV 3处理的小鼠
显示血清Cu生物标志物铜蓝蛋白的活性降低和肿瘤生长减少。在这
根据该提议,我们将进行结构指导优化,以鉴定具有更高效力的MKV 3类似物,
药物样性质(目的1);进行药代动力学研究,以确定适用于
药效学研究(目的2);并评估最有利的MKV 3类似物在小鼠乳腺癌模型中的作用
癌症(目标3)。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Regulation of Atp7a RNA contributes to differentiation-dependent Cu redistribution in skeletal muscle cells.
ATP7A RNA的调节有助于骨骼肌细胞中分化依赖性的CU重新分布。
- DOI:10.1093/mtomcs/mfad042
- 发表时间:2023-07-10
- 期刊:
- 影响因子:3.4
- 作者:Whitlow, Thomas J.;Zhang, Yu;Ferguson, Nathan;Perez, Alexandra M.;Patel, Hemchandra;Link-Kemp, Josephine A.;Larson, Ethan M.;Mezzell, Allison T.;Shanbhag, Vinit C.;Petris, Michael J.;Vest, Katherine E.
- 通讯作者:Vest, Katherine E.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL J. PETRIS其他文献
MICHAEL J. PETRIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL J. PETRIS', 18)}}的其他基金
Targeting vulnerabilities in copper metabolism in the development of cancer therapies
针对癌症疗法开发中铜代谢的脆弱性
- 批准号:
10461152 - 财政年份:2021
- 资助金额:
$ 47.43万 - 项目类别:
Targeting vulnerabilities in copper metabolism in the development of cancer therapies
针对癌症疗法开发中铜代谢的脆弱性
- 批准号:
10280230 - 财政年份:2021
- 资助金额:
$ 47.43万 - 项目类别:
Novel roles of copper in adaptive responses to hypoxia
铜在缺氧适应性反应中的新作用
- 批准号:
10614637 - 财政年份:2021
- 资助金额:
$ 47.43万 - 项目类别:
Novel roles of copper in adaptive responses to hypoxia
铜在缺氧适应性反应中的新作用
- 批准号:
10345243 - 财政年份:2021
- 资助金额:
$ 47.43万 - 项目类别:
2017 Cell Biology of Metals Gordon Research Conference and Gordon Research Seminar
2017金属细胞生物学戈登研究会议暨戈登研究研讨会
- 批准号:
9328227 - 财政年份:2017
- 资助金额:
$ 47.43万 - 项目类别:
Copper metabolism as a unique vulnerability in cancer
铜代谢是癌症的独特弱点
- 批准号:
9178063 - 财政年份:2014
- 资助金额:
$ 47.43万 - 项目类别:
Copper metabolism as a unique vulnerability in cancer
铜代谢是癌症的独特弱点
- 批准号:
8974819 - 财政年份:2014
- 资助金额:
$ 47.43万 - 项目类别:
Copper metabolism as a unique vulnerability in cancer
铜代谢是癌症的独特弱点
- 批准号:
8797173 - 财政年份:2014
- 资助金额:
$ 47.43万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 47.43万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 47.43万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 47.43万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 47.43万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 47.43万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 47.43万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 47.43万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 47.43万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 47.43万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 47.43万 - 项目类别:
Research Grant